Platform & Strategies
Publications
HomePlatform & StrategiesPublications
| NO | Pipeline | Name | Title | |
|---|---|---|---|---|
| 5 | ABL111 | AACR 2020 | AACR 2020 / Claudin 18.2 x 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation |
|
| 4 | ABL001 | PEPTALK 2020 | PEPTALK 2020 / Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors |
|
| 3 | ABL503 | PEGS 2019 | PEGS 2019 / The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation |
|
| 2 | ABL001 | ASCO 2019 | ASCO 2019 / Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer |
|
| 1 | ABL001 | PEGS 2017 | PEGS 2017 / Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 |
|
-
AACR 2020 / Claudin 18.2 x 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation
-
PEPTALK 2020 / Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors
-
PEGS 2019 / The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation
-
ASCO 2019 / Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer
-
PEGS 2017 / Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001